Sales of Samsung Bioepis' 3 biosimilars reach $200 million in Europe in Q1
Apr 23, 2020
South Korean drugmaker Samsung Bioepis Co. said Thursday that sales of its three biosimilar products posted a record high of $200 million in Europe during the first quarter. Combined sales of the three autoimmune biosimilars -- Benepali, Flixabi and Imraldi -- came to $219 million in the January-March period, up 25 percent from the same period a year earlier. The company cited a first-quarter earnings report of its US partner Biogen. Samsung Bioepis is a joint venture between Samsung Biologic